GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS)
CNY 11.84
(-0.34%)
CNY 11.84
(-0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 335.82 Million CNY | 19.46% |
| 2022 | 225.54 Million CNY | 25.87% |
| 2021 | 179.19 Million CNY | 59.61% |
| 2020 | 112.27 Million CNY | -27.38% |
| 2019 | 154.59 Million CNY | 54.94% |
| 2018 | 99.77 Million CNY | 13.99% |
| 2017 | 87.52 Million CNY | 31.4% |
| 2016 | 66.61 Million CNY | 31.04% |
| 2015 | 50.83 Million CNY | 57.64% |
| 2014 | 32.24 Million CNY | 91.85% |
| 2013 | 16.8 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 93.24 Million CNY | 35.68% |
| 2024 Q1 | 73.11 Million CNY | -27.08% |
| 2024 Q2 | 68.72 Million CNY | -6.01% |
| 2023 Q3 | 66.05 Million CNY | 21.38% |
| 2023 Q4 | 100.26 Million CNY | 51.8% |
| 2023 FY | 269.43 Million CNY | 19.46% |
| 2023 Q1 | 63.38 Million CNY | -43.59% |
| 2023 Q2 | 54.41 Million CNY | -14.15% |
| 2022 Q2 | 45.54 Million CNY | 87.07% |
| 2022 Q1 | 24.34 Million CNY | -48.06% |
| 2022 FY | 225.54 Million CNY | 25.87% |
| 2022 Q4 | 112.35 Million CNY | 159.45% |
| 2022 Q3 | 43.3 Million CNY | -4.91% |
| 2021 Q4 | 46.87 Million CNY | -3.27% |
| 2021 FY | 179.19 Million CNY | 59.61% |
| 2021 Q2 | 55.61 Million CNY | 96.89% |
| 2021 Q1 | 28.24 Million CNY | -46.88% |
| 2021 Q3 | 48.45 Million CNY | -12.87% |
| 2020 Q4 | 53.17 Million CNY | 2264.12% |
| 2020 FY | 112.27 Million CNY | -27.38% |
| 2020 Q2 | 24.26 Million CNY | -25.51% |
| 2020 Q1 | 32.57 Million CNY | -27.86% |
| 2020 Q3 | 2.24 Million CNY | -90.73% |
| 2019 Q1 | 25.43 Million CNY | 0.0% |
| 2019 FY | 154.59 Million CNY | 54.94% |
| 2019 Q4 | 45.15 Million CNY | -1.53% |
| 2019 Q3 | 45.85 Million CNY | 20.22% |
| 2019 Q2 | 38.14 Million CNY | 49.94% |
| 2018 FY | 99.77 Million CNY | 13.99% |
| 2018 Q2 | 35.31 Million CNY | 172.43% |
| 2018 Q1 | 12.96 Million CNY | -54.75% |
| 2017 FY | 87.52 Million CNY | 31.4% |
| 2017 Q1 | 11.6 Million CNY | -37.77% |
| 2017 Q3 | 28.65 Million CNY | 0.0% |
| 2017 Q4 | 28.65 Million CNY | 0.0% |
| 2016 Q4 | 18.64 Million CNY | 0.0% |
| 2016 Q1 | 15.93 Million CNY | 7.14% |
| 2016 Q2 | 15.93 Million CNY | -0.0% |
| 2016 Q3 | 18.64 Million CNY | 16.97% |
| 2016 FY | 66.61 Million CNY | 31.04% |
| 2015 Q3 | 14.87 Million CNY | 37.55% |
| 2015 Q1 | 10.81 Million CNY | 20.72% |
| 2015 Q4 | 14.87 Million CNY | 0.0% |
| 2015 Q2 | 10.81 Million CNY | -0.0% |
| 2015 FY | 50.83 Million CNY | 57.64% |
| 2014 Q3 | 8.95 Million CNY | 21.94% |
| 2014 Q1 | 7.34 Million CNY | 0.0% |
| 2014 FY | 32.24 Million CNY | 91.85% |
| 2014 Q2 | 7.34 Million CNY | -0.0% |
| 2014 Q4 | 8.95 Million CNY | 0.0% |
| 2013 FY | 16.8 Million CNY | 0.0% |